A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Phase 2 Completed 350 enrolled Kyowa Kirin, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multicenter, randomized, double-blind, placebo-controlled, group-comparison study to investigate the safety and efficacy of OPC-262 in patients with type 2 diabetes

Timeline

Start: 2009-01
Primary completion: 2010-03
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	1 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	2.5 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	5 mg	Oral

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications